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Abstract 
The aim of this study was to analyze gene expression in blood of patients with newly-
diagnosed schizophrenia during their first psychotic episode and subsequent 
remission. Whole blood samples were obtained from 32 untreated patients presenting 
with their first psychotic episode suggestive of schizophrenia and 32 age- and gender- 
matched controls. Using Affymetrix micoarrays, we identified significantly altered 
expression of 180 gene probes in psychotic patients compared to controls. A subset of 
4 significantly changed genes was further confirmed with QRT PCR. The following 
genes were significantly altered in patients: glucose transporter, SLC2A3 (p<0.001) 
and actin assembly factor DAAM2 (p<0.001) were increased, whereas translation, 
zinc metallopeptidase, neurolysin 1 and myosin C were significantly decreased 
(p<0.05). Expression of these candidate markers was also analyzed in a longitudinal 
study (12-24 months) in 12 patients who achieved full remission. Interestingly, 
expression of DAAM2 returned to control levels in patients who were in remission 
after their first psychotic episode, suggesting that its expression correlates with 
diseases progression and/or response to treatment. In summary, we identified changes 
of gene expression from peripheral blood which might help discriminate patients with 
schizophrenia from controls. While these results are promising, especially for 
DAAM2 whose polymorphic variants have been found significantly associated with 
schizophrenia, it will be important to analyze larger cohorts of patients in order to 
firmly establish changes in gene expression as blood markers of schizophrenia. 
Key words: schizophrenia, gene expression, biomarkers, blood, DAAM2 
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1. INTRODUCTION 
 
Schizophrenia is one of the most disabling psychiatric illnesses, affecting about 1% of 
population, with no significant differences in its prevalence among countries (Sadock 
& Sadock, 2003). Although the term schizophrenia is used to describe a relatively 
heterogeneous group of clinical presentations, in majority of cases, schizophrenia is a 
chronic illness with a recurrent course, characterized by alternating periods of acute 
psychotic illness and their remission. A prodromal stage which may last for several 
years prior to presentation of acute psychotic symptoms usually precedes the first 
acute psychosis. Duration of at least six months of the first episode of psychosis is 
highly suggestive of schizophrenia. With each new episode of acute psychosis, the 
patient condition deteriorates further, until a stage with predominately negative and 
cognitive symptoms is reached. 
The pathogenesis of this illness is still largely unknown and the diagnosis of 
schizophrenia is based on its clinical presentation. In both clinical and research 
settings, DSM-IV criteria are usually applied (APA, 1994). The severity of symptoms 
is usually determined using standardized measurement tools, such as positive and 
negative syndrome scale (PANSS) (Kay et al. 1987). Adequate treatment response of 
an acute episode is characterized by a 50% reduction of the severity of acute 
symptoms after 6 weeks (early treatment response) or 12 weeks of treatment (late 
treatment response) (Kane et al. 2003). Strict remission criteria were proposed by 
Andreasen et al. (2005). 
To objectify the diagnosis and course of treatment of this illness, an effort has been 
made to identify a biological correlate of schizophrenia (Sadock & Sadock, 2003). For 
example, the search for biomarkers revealed neuropathological (Shapiro, 1993; 
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Farrow et al. 2005) and neurophysiologic (Callicott et al. 1999) abnormalities, as well 
as alterations in neurotransmitter function (Stahl, 2000), neurotrophic factors (Parikh 
et al. 2003) and gene expression in prefrontal cortex (Mirnics et al. 2001). 
For clinical purpose, a biomarker which might be detected by non- invasive methods 
would be desirable. To this end, several authors identified possible biomarkers for 
schizophrenia from peripheral blood, including neurotransmitter metabolite levels, 
stress hormones (Sadock & Sadock, 2003), markers of immune response (Gladkevich 
et al. 2004) and fatty acids (Fenton et al. 2000). Recently, it has been suggested that 
gene expression analysis of peripheral blood microarrays might become a potentially 
useful tool in detecting markers of presence and progression of a variety of 
neuropsychiatric diseases including schizophrenia (Gladkevich et al. 2004; Middleton 
et al. 2005). 
 The focus of this study has been to examine gene expression changes during 
the first psychotic episode and subsequent remission in newly-diagnosed patients with 
schizophrenia. This study design allows for monitoring of changes in gene expression 
in relation to disease progression and response to treatment. 
  
2. SUBJECTS AND METHODS 
 
2. 1. Subjects 
 
We analyzed 32 previously untreated patients presenting with their first psychotic 
episode suggestive of schizophrenia, admitted at Zagreb University Hospital Center in 
the period from 2004 to 2007. All patients were over 18 years, Caucasian, met criteria 
for a diagnosis for schizophrenia following DSM-IV guidelines (2). The inclusive 
 5
criteria were as follows: (1) Acute psychosis defined by the score of least 80 on the 
positive and negative syndrome scale (PANSS) (Kay et al. 1987) and at least graded 
by moderate severity on at least two positive symptoms (2) DSM - IV criteria met for 
schizophrenia; (3) no other neurological diseases, mental disorders, drug and alcohol 
abuse and eating disorders, no other serious somatic illness, including acute 
infections; (4) normal blood counts; (5) positive family history of schizophrenia.  
The severity of illness was assessed using the PANSS scale, by two different 
psychiatrists. Global functioning was assessed using Global Assessment of 
Functioning (GAF) Scale (DSM-IV). All relevant sociodemographic, including ethnic 
and geographical background, and clinical data were assessed during the clinical 
interview (Table 1). 
Controls were all age and sex matched healthy subjects of the same ethnic and 
geographical background as patients, and were matched also in respect to blood count 
composition.  
 
2. 2. Study protocol  
 
The study was conducted in two steps.  
After a careful selection of patients who fulfilled all above mentioned inclusion and 
exclusion criteria, in the first study point whole blood samples were obtained from all 
patients prior to the administration of medication. At the same time whole blood 
samples were obtained from sex- and age- matched controls. After the blood samples 
were obtained, all patients received a second generation antipsychotic (SGA) 
according to the standard clinical practice. 
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The next step of the study design involved the follow up of all subjects for at least one 
year period, during which all subjects continued the pharmacological treatment. The 
follow-up consisted of regular outpatient visits which included psychiatric interviews 
and assessments of the severity of illness using PANSS and GAF. Full remission was 
determined using strict criteria (Andreasen et al. 2005). Additionally, only those who 
returned to the previous level of functioning (work, school) assessed using GAF were 
regarded as remitted. Out of 32 patients, only 14 patients fulfilled the requirements for 
full remission and returned to the previous level of functioning, and were included in 
this second part of the study, but two patients refused to participate further in the 
study. The rest of patients achieved only partial remission even after 2-year follow up 
(N=15), were lost from the follow up soon after hospital discharge (N=2) whereas one 
patient committed suicide.  
All participants gave informed consent for participation in the study, and they were 
given explanations and answers about the procedure of the study. The study protocol 
was approved by the Hospital Ethical Committee of the Zagreb University Hospital 
Centre. 
 
2. 3. RNA expression analysis 
 
2.3.1. Isolation of the blood samples 
 
In the first step, blood samples from a total of 32 patients with schizophrenia (8 male 
and 24 female) and 32 sex and age matched controls were obtained. In the second 
step, blood samples from 12 patients (1 male and 11 female) who achieved full 
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remission after a 12 to 24 month-period were obtained. Blood specimens of cases and 
controls were collected and assayed in parallel. 
Total RNA from blood was extracted by using PAXgene blood RNA kit (Qiagen). All 
samples were treated with the RNase-free DNase set (Qiagen). The quality of total 
RNA was analyzed by using the RNA 6000 Nano LabChip on a 2100 Bioanalyzer 
(Agilent Technologies, Palo Alto, CA). Microarray analysis was performed using 
U133A GeneChips (Affymetrix) with 22,283 30-mer probes (approximately 11000 
genes). Total RNA was processed using Affymetrix protocol: 4 µg of high quality 
RNA was reverse-transcribed, purified (Invitrogen, Qiagen) and than used as a 
template for in-vitro transcription by using T7 MEGA script reagents and biotin-11-
UTP. Biotin labeled RNA was purified with the RNeasy kit (Qiagen), hybridized to 
chips, fluorescently tagged and scanned. The regular quality measures for Affymetrix 
GeneChip were used.  
 
2.2. Quantitative RT-PCR analysis 
 
Reverse transcription was performed using total RNA isolated from blood, processed 
with the SuperScript II first strand synthesis for RT-PCR following the manufacturers 
protocol (Invitrogen). For detection in quantitative RT-PCR SYBR green was used. 
Primers were as follows: catenin (cadherin-associated protein) beta 1 (CTNNB1) F 5’ 
ATGCGTTCTCCTCAGATGGT and R 5’ TGGGAAAGGTTATGCAAGGT; 
RING1 and YY1 binding protein (RYBP) F 5’ CGCTCCTCATCGACATCCT and 5’ 
R AGCCCTTGTCTGTGCTCTCT; ring finger protein 10 (RFN10) F 5’ 
GGCAAGTACCCAGAAGTCCA and R 5’ GCAGAATCAGAGGAGCAGGT; 
glucose transporter, SLC2A3 F 5’ TGCTTAGGAGAGACCGAGTGA and R 5’ 
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ATATCAGAACCCAAGGGAGGA; neurolysin 1 (NLN-1) F 5' 
GGCTGAACTTGGTGCTCTTC and R 5' TAGTTTGGCCACCTTGGTTC; myosin 
C (MYO1C) F 5' ATCCCATTATGAGCCAGTGC and R 5' 
CATCATTGGGTTTGATGCAG; actin assembly factor (DAAM2) F 5' 
GCTGCCAAAGTCAACCTAGC and R 5' CTTGTCCCTGGCCTCATTTA; ß-actin 
(ACTB) F 5' GGACTTCGAGCAAGAGATGG and R 5' 
AGCACTGTGTTGGCGTACAG. ß-actin was used as an internal control. We used 
two copies of each sample.  
 
3. Statistical analysis 
 
MAS (version 5.0) was used for the calculation of signal values on microarrays and 
ACCESS for filtering the statistically significant genes. Calculation of maximal 
values of expression, t-tests (two sided) and ratios of change were performed using 
EXCEL, Microsoft office. In the further analysis of the microarray data, only genes 
that fulfilled three conditions were included: 1. MAS "signal intensity" above the 
"target intensity" of 100 to reduce the possibility of the error due to technical noise; 2. 
expression ratio of average psychosis/control >1.8 or <0.6; 3. p<0.05 on two sided 
student t-test. P values were corrected for multiple testing using a false discovery rate 
approach. Affymetrix microarrays were normalized using Robust Multi-array 
Averaging.  Analysis was performed using R version 2.3 and the Bioconductor 
packages affy and limma (http://www.bioconductor.org) (Gentleman et al. 2004). 
Where multiple probe sets were assigned to the same gene only the statistics from the 
probe with the greatest evidence for differential expression were retained. Affymetrix 
annotations (version 24) were used for probe-set-to-gene assignments. 
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For QRT-PCR data, the differences in the Δ Ct between the genes and ß-actin were 
used for t-test statistics. Differences in expression levels of each gene between 
patients and controls were analyzed using t-test for independent samples, two sided, 
whereas differences in expression levels of each gene between patients in acute 
psychosis and their remission were analyzed using t-test for dependent samples, two 
sided. The average fold change = 2 – (average Δ Ct ) was computed using the average Δ Δ 
Ct between patients and controls and between patients in acute psychosis and their 
remission. Mean standard error SEM was calculated using Δ Ct. 
We used descriptive statistics for showing clinical features at baseline. The 
associations of expression levels of each gene (Δ Ct between the genes and ß-actin) 
and a variety of clinical features were studied using multivariate analysis. No changes 
were observed in beta-actin among various groups examined. 
For all clinical and QRT-PCR data analysis EXCEL, Microsoft office and SPSS 13.0 
were used. P value of less than 0.05 was considered statistically significant.  
 
3. RESULTS 
 
3.1. Clinical features 
 
Description of clinical features of the patients is shown in Table 1. 
 
3.2. Microarray analysis 
 
Using Affymetric micorarray platform we identified 180 gene probes that were 
significantly changed in patients with schizophrenia compared to healthy controls and 
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fulfilled all three requirements (p<0.05, expression level 100, average expression ratio 
>1.8 or <0.6). 115 gene probes were down-regulated, whereas 65 were upregulated 
compared to controls (Supplementary table). Genes with altered expression include 
genes from different functional groups: transcription/RNA processing, ubiquitin, 
lipid/glucose/protein metabolism, signal transduction, cytoskeleton and others 
(analyzed with GeneOntology). 
 
3.3. QRT-PCR analysis 
 
Out of 180 significantly altered gene probes we selected a subset of 7 potential 
markers for further confirmation with QRT PCR: catenin (cadherin-associated 
protein), beta 1 (CTNNB1), RING1 and YY1 binding protein (RYBP), ring finger 
protein 10 (RFN10), glucose transporter (SLC2A3), zinc metallopeptidase, neurolysin 
1 (NLN-1), myosin C (MYO1C) and actin assembly factor (DAAM2). Potential 
genetic markers were selected based on their expression levels (MAF), significance of 
changes between psychosis vs. controls (p-values), expression ratios of psychosis vs. 
controls and their function, as reported in the literature.   
In total, 32 patients and 32 age- and sex- matched controls were tested. Using this 
approach, the following 4 genes were validated as significantly altered in patients 
compared to controls: glucose transporter, SLC2A3 (t=-4.678, p<0.001) and actin 
assembly factor DAAM2 (t=-3.709, p<0.001) were increased, whereas zinc 
metallopeptidase, neurolysin 1 (t=2.838, p=0.006) and myosin C (t=2.148, p=0.036) 
were significantly decreased (Figure 1). It is important to note that our PCR primers 
for SLC2A3 cannot distinguish SLC2A3 from another glucose transporter SLC2A14.  
Nevertheless, our microarray datasets showed that only SLC2A3-specific probe gave 
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significant result, suggesting that SLC2A3 is the likely gene altered in patients.  We 
found no significant associations of sociodemoghraphic features (including age, sex, 
duration of untreated psychosis and family history of psychiatric disorders) with gene 
expression in the additional univariate analysis (data not shown). 
 
 
3.4. QRT-PCR analysis for disease progression  
 
The second step involved testing gene expression of the 4 validated candidate markers 
in 12 out of 32 patients who achieved full remission during a longitudinal study (12-
24 months). Interestingly, expression of DAAM2 significantly decreased in patients 
who were in remission after their first psychotic episode (t=-3.007, p=0.012), and 
returned to almost control levels (Figure 2). There were no significant changes of 
expression of other 3 genes in patients in their state of acute psychosis compared to 
their state of remission (Figure 2). While there was significant difference in the 
expression of neurolysin 1 in remission compared to controls (t=-3.172, p=0.003), we 
found no significant differences in the expression of other genes in these groups 
(Figure 2).  
 12
4. DISCUSSION 
 
In this study we used microarrays to detect alterations of gene expression in blood 
samples from patients with acute psychosis compared to healthy controls. Using real-
time PCR, we confirmed altered expression of a subset of 4 genes, of which one gene 
(DAAM2) returned to controls levels in patients who achieved complete clinical 
remission. These results suggest that expression of DAAM2 correlated with disease 
progression and/or response to treatment.   
Interestingly, Proitsi et al. (2008) found significant associations of polymorphic 
variants of DAAM2 gene and schizophrenia in a family trios (two haplotypic 
associations) and combined family trios and case control sample (single marker 
association), although the authors did not confirm this finding in the case - control 
sample. Although their findings are inconclusive, it might suggest that DAAM2 
polymorphic loci might be associated with a greater risk for schizophrenia. In light of 
our findings, it would be of interest to examine whether these polymorphisms are 
associated with altered expression of DAAM2 observed in our study. Although 
DAAM2 is expressed in brain tissues, and it may have a role in neuronal cell 
differentiation (Kida et al. 2004), it precise function remains unknown. Interestingly, 
we observed that alteration in expression of DAAM2 in psychotic patients returned to 
baseline levels upon complete clinical remission, suggesting that DAAM2 may 
represent a state marker of the disease. Alternatively, changes in DAAM2 expression 
may be due to treatment with the antipsychotics. Although there were no significant 
differences in DAAM2 expression in regard to the type of antipsychotic used (data 
not shown), the influence of medication on DAAM2 expression cannot be completely 
excluded. It would be of interest to examine expression of DAAM2 in extended 
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follow-up studies and include patients who discontinue the treatment after a 
prolonged period of full remission. 
In contrast to DAAM2, NLN-1 expression in patients with schizophrenia is 
consistently decreased compared to controls, regardless of the state of the illness. 
Pollio et al. (2008) reported that the overexpression of NLN-1 was neuroprotective 
against toxicity of amyloid ß and also observed it in brain of humans with Alzheimer 
disease. Considering the neurodegeneration observed in patients with schizophrenia 
(Benes, 2000), it would be of interest to examine the expression of NLN-1 in blood 
and brain of patients in schizophrenia as well in follow up studies also involving 
patients with chronic illness. 
 
Gene expression analysis of peripheral blood using microarray have become 
increasingly accepted as a potentially useful tool in detecting markers of presence and 
progression of a variety of neuropsychiatric diseases. Several previous reports found 
differentially expressed genes in peripheral blood of patients with schizophrenia 
compared to their unaffected siblings (Vawter et al. 2004; Middleton et al. 2005; 
Kakiuchi et al. 2008) or to controls (Glatt et al. 2005; Tsuang et al. 2005; Numata et 
al. 2007). The usual confounders include methodological differences in data 
collection, heterogeneity of clinical presentations of the illness (Numata et al. 2007) 
and medications used by study subjects (Colantuoni et al. 2008). In addition, 
differences in data analysis arise from the type of microarray assays and the 
methodology of analysis applied (Ludwig and Weinstein, 2005). 
Newer studies tried to overcome these confounders by including patients with first 
episode psychosis who were drug free prior to their study enrollments (Zvara el al. 
2005; Numata et al. 2007; Numata et al. 2008; Suzuki et al. 2008; Zhang et al. 2008). 
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However, with the exception of the recent studies, all other studies were cross 
sectional - blood samples were drawn from patients only in their acute psychotic state, 
and did not address the episodic nature of the illness.  
Zhang et al. (2008), found decreased expression of neuregulin1 in the blood of 
patients with schizophrenia compared to controls, which increased with 4-week 
antipsychotic treatment. Although we observed similar but non-significant trend in 
our datasets (data not shown), neuregulin 1 was not selected for further validation also 
since its MAS “signal intensity” was below 100.  
Similarly, we did not observe significant differences in the expression levels of 
transforming grow factor-ß receptor 2 (TGFBR2), as reported by Numata et al., 
(2008). They found that TGFBR2 mRNA levels in medication free patients with 
schizophrenia were significantly higher than those of control subjects and decreased 
to control levels after several week of antipsychotic treatment. However, TGFBR2 
mRNA levels did not correlate with the severity of illness measured with Brief 
Psychiatric Rating Scale (BPRS). Suzuki et al. (2008) found that levels of very low 
density lipoprotein receptor (VLDLR) mRNA in drug-naive patients with 
schizophrenia were significantly lower than those of controls and showed significant 
increases with respect to baseline after six months of antipsychotic treatment, with a 
negative correlation between VLDLR mRNA levels and the severity of clinical 
symptoms, measured with BPRS. In our study, VDLDR was also not selected for 
QRT-PCR validation since its MAS “signal intensity” was below 100. 
Although we used a study design which makes our results comparable to the study of 
Numata et al. (2008), Suzuki et al. (2008) and Zhang et al. (2008) (inclusion of only 
drug- naive patients and follow up of the patients), we took further steps to reduce the 
heterogeneity of the samples by selecting only patients with a severe acute episode of 
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psychosis, and having at least one close relative affected with schizophrenia. Also, to 
further confirm the correlations of potential markers with disease progression, the 
second blood draw was determined by the clinical presentation and not by a 
predefined time frame - we analyzed gene expression in blood of the same patients 
after they have achieved full remission following very strict criteria (Andreasen et al. 
2005) and returned to their previous level of functioning.    
Although we found no significant differences in gene expression of the investigated 
markers in association with patient gender, the predominance of the female patients 
especially in our validation studies might have masked possible gender differences. 
Despite the fact that our results are promising it will be critically important to validate 
these findings in larger cohorts of patients in a follow up design in order to firmly 
establish changes in gene expression as blood markers of schizophrenia. 
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Table 1. Clinical features of the patients (N=32) at the time of their hospital admission  
 
Feature Value 
Male 8 (25%) Sex (N (%)) 
Female 24 (75%) 
Age (years+/-SD) 28.15+/-7.9 
Education (years+/-SD) 11.93+/-9.67 
Duration of untreated illness 
(months+/-SD) 
20.61+/-23.15  
Schizophrenia-related in close relatives 20 (62.4%) 
Schizophrenia-related multiple members 6 (18.8%) 
Schizophrenia-related in distant relatives 3 (9.4%) 
Family history of psychiatric 
disorders (N(%)) 
Schizophrenia-related in distant relatives and other 
psyciatric disorder in close relatives (alcholol addictions) 
3 (9.4%) 
Positive PANSS (mean+/-SD) 32+/-5.5 
Negative PANSS (mean+/-SD) 24+/-5.5 
General PANSS (mean+/-SD) 46+/-8.9 
Total PANSS (mean+/-SD) 102+/-16.5 
GAF (mean+/-SD) 26.68+/-8 
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Figure 1. Fold changes in expression of 7 marker genes in 32 patients with psychosis 
compared to matched controls. Columns represent the average fold change = 2 – (average 
Δ Ct) of expression of the genes analyzed with QRT-PCR. SEM was calculated using Δ 
Ct. The difference in mean Δ Ct between patients and controls was tested using t-tests 
for independent samples, 2-sided.  
* p<0.05 
** p<0.001 
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Figure 2. Fold changes in expression of 4 validated marker genes in 12 patients in the 
state of acute psychosis relative to controls and patients in remission relative to 
controls. Columns represent the average fold change = 2 – (average Δ Ct) of expression of 
the 4 genes analyzed with QRT-PCR. 
a* p<0.05, patients in acute psychosis vs. controls (t-tests for independent samples, 2-
sided: NLN1: t=2.593, p=0.013; DAAM2: t=-2.671, p=0.011; SLC2A3: t=-3.559, 
p=0.001) 
b* p=0.003, patients in remission vs. controls (t-tests for independent samples, 2-
sided)  
*p=0.012, patients in acute psychosis vs. remission (t-tests for dependent samples, 2-
sided) 
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Supplementary table. Differential RNA expression levels in patients with psychosis 
and healthy matched control obtained with Affymetric micorarray platform. 180 gene 
probes are shown that were significantly changed in patients with acute psychosis 
compared to healthy controls (p<0.05, expression level 100, average expression ratio 
>1.8 or <0.6).    
 
 
Gene Probe Gene  Symbol 
Up-regulated   
 Transcription/RNA processing 
 201844_s_at RING1 and YY1 binding protein RYBP 
 1560228_at snail homolog 3 (Drosophila) SNAI3 
 209253_at sorbin and SH3 domain containing 3 SORBS3 
 
216842_x_at 
similar to RNA binding motif protein, Y chromosome, 
family 2 member B 
RNA binding motif protein, Y-linked, family 1, member 
A1 
RNA binding motif protein, Y-linked, family 1, member B 
RNA binding motif protein, Y-linked, family 1, member D 
RNA binding motif protein, Y-linked, family 1, member E 
RNA binding motif protein, Y-linked, family 1, member F 
RNA binding motif protein, Y-linked, family 1, member H 
RNA binding motif protein, Y-linked, family 1, member J 
RNA binding motif protein, Y-linked, family 3, member A 
pseudogene 
RBM, RBM 
RBMY1A1 
RBMY1B 
RBMY1D 
RBMY1E 
RBMY1F 
RBMY1H 
RBMY1J 
RBMY3AP 
 1558215_s_at upstream binding transcription factor, RNA polymerase I UBTF 
 235145_at zinc finger and BTB domain containing 7B ZBTB7B 
 244752_at zinc finger protein 438 ZNF438 
 218222_x_at aryl hydrocarbon receptor nuclear translocator ARNT 
 226416_at three prime histone mRNA exonuclease 1 ERI1 
 
213098_at 
RCD1 required for cell differentiation1 homolog (S. 
pombe) RQCD1 
 216925_s_at T-cell acute lymphocitic leukemia 1 TAL1 
 
214263_x_at 
polymerase (RNA) II (DNA directed) polypeptide C, 
33kDa POLR2C 
    
 Signal transduction  
 222453_at cytochrome b reductase 1 CYBRD1 
 207721_x_at histidine triad nucleotide binding protein 1 HINT1 
 
212555_at 
similar to protein kinase, cAMP-dependent, regulatory, 
type I, beta protein kinase 
LOC729623 
PRKAR1B 
 224859_at CD276 molecule CD276 
 210773_s_at formyl peptide receptor 2 FPR2 
 229395_at syntaxin 4 STX4 
 227067_x_at Notch homolog 2 (Drosophila) N-terminal like NOTCH2NL 
 226878_at major histocompatibility complex, class II, DO alpha HLA-DOA 
 206614_at growth differentiation factor 5 GDF5 
 208304_at chemokine (C-C motif) receptor 3 CCR3 
 216388_s_at leukotriene B4 receptor LTB4R 
 216407_at Vac14 homolog (S. cerevisiae) VAC14 
 231029_at coagulation factor V (proaccelerin, labile factor F5 
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 227057_at Rho GTPase activating protein 27 ARHGAP27 
 217808_s_at mitogen-activated protein kinase associated protein 1 MAPKAP1 
 221568_s_at lin-7 homolog C (C. elegans) LIN7C 
 
228263_at 
GRP1 (general receptor for phosphoinositides 1)-
associated scaffold protein GRASP 
 217422_s_at CD22 molecule CD22 
 201137_s_at major histocompatibility complex, class II, DP beta 1 HLA-DPB1 
    
 Glucose/Lipid/Protein metabolism  
 225286_at 
223696_at 
225280_x_at arylsulfatase D ARSD 
 219707_at copine VII CPNE7 
 218292_s_at protein kinase, AMP-activated, gamma 2 non-catalytic PRKAG2 
 
202499_s_at 
solute carrier family 2 (facilitated glucose transporter), 
member 3 SLC2A3 
 
203916_at 
N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 
2 NDST2 
 222622_at phosphoglycolate phosphatase PGP 
 212246_at multiple coagulation factor deficiency 2 MCFD2 
 201554_x_at glycogenin 1 GYG1 
 1554385_a_at peptidyl arginine deiminase, type II PADI2 
 202826_at serine peptidase inhibitor, Kunitz type 1 SPINT1 
    
 DNA processing/cell cycle  
 225844_at polymerase (DNA-directed), epsilon 4 (p12 subunit POLE4 
 202769_at cyclin G2 CCNG2 
 
202414_at 
excision repair cross-complementing rodent repair 
deficiency, complementation group 5 ERCC5 
 
208583_x_at 
histone cluster 1, H2ag 
histone cluster 1, H2ah 
histone cluster 1, H2ai 
histone cluster 1, H2aj 
histone cluster 1, H2ak 
histone cluster 1, H2al 
histone cluster 1, H2am 
histone cluster 1, H3f 
HIST1H2AG 
HIST1H2AH 
HIST1H2AI 
HIST1H2AJ 
HIST1H2AK 
HIST1H2AL 
HIST1H2AM 
HIST1H3F 
    
 Others   
 234276_at unknown  
 227807_at poly (ADP-ribose) polymerase family, member 9 PARP9 
 209264_s_at tetraspanin 4 TSPAN4 
 
217326_x_at 
T cell receptor beta constant 1 
T cell receptor beta constant 2 
T cell receptor beta variable 19 
T cell receptor beta variable 7-4 
T cell receptor beta variable 7-6 
T cell receptor beta variable 7-7 
T cell receptor beta variable 7-8 
TRBC1 
TRBC2 
TRBV19 
TRBV7-4 
TRBV7-6 
TRBV7-7 
TRBV7- 
 229668_at hypothetical protein LOC90393 LOC9039 
 222252_x_at 
224513_s_at ubiquilin 4 UBQLN4 
 229182_at unknown  
 222139_at KIAA1466 gene KIAA1466 
 240233_at unknown  
 237779_at unknown  
 212357_at family with sequence similarity 168, member A FAM168A 
 223351_at chromosome 17 open reading frame 80 C17orf8 
 204787_at V-set and immunoglobulin domain containing 4 VSIG4 
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 226630_at chromosome 14 open reading frame 106 C14orf106 
 1553153_at 
ATPase, H+ transporting, lysosomal 38kDa, V0 subunit 
d2 ATP6V0D2 
 212793_at dishevelled associated activator of morphogenesis 2 DAAM2 
 223777_at hypothetical LOC84771 MGC13005 
    
Down-regulated   
    
 Transcription/RNA processing  
 1554015_a_at chromodomain helicase DNA binding protein 2 CHD2 
 1560228_at snail homolog 3 (Drosophila SNAI3 
 
208632_at 
207801_s_at ring finger protein 10 RNF10 
 243496_at RAB18, member RAS oncogene family RAB18 
 205453_at homeobox B2 HOXB2 
 242706_s_at mediator complex subunit 23 MED23 
 224767_at Ribosomal protein L37 RPL37 
 235623_at Elongation protein 2 homolog (S. cerevisiae ELP2 
 213529_at zinc finger protein 688 ZNF688 
 241402_at tRNA splicing endonuclease 54 homolog (S. cerevisiae TSEN54 
 231203_at similar to hCG1651427 LOC100129633 
 1560922_s_at zinc finger protein 169 ZNF16 
 201533_at catenin (cadherin-associated protein), beta 1, 88kDa CTNNB1 
   
 Signal transduction  
 213013_at mitogen-activated protein kinase 8 interacting protein 1 MAPK8IP1 
 235241_at solute carrier family 38, member 9 SLC38A9 
 205336_at parvalbumin PVALB 
 214567_s_at chemokine (C motif) ligand 1 XCL1, XCL2 
 225562_at RAS p21 protein activator 3 RASA3 
 212841_s_at 
PTPRF interacting protein, binding protein 2 (liprin beta 
2) PPFIBP2 
 213688_at 
calmodulin 1 (phosphorylase kinase, delta) 
calmodulin 2 (phosphorylase kinase, delta) 
calmodulin 3 (phosphorylase kinase, delta) 
CALM1 
CALM2 
CALM3 
 215179_x_at Placental growth factor PGF 
 201314_at Serine/threonine kinase 25 (STE20) homolog, yeast STK25 
 215404_x_at fibroblast growth factor receptor  FGFR1 
 212070_at G protein-coupled receptor 56 GPR56 
 212821_at 
pleckstrin homology domain containing, family G (with 
RhoGef domain) member 3 PLEKHG3 
 230464_at sphingosine-1-phosphate receptor 5 S1PR5 
 233101_at myotubularin related protein 9 MTMR9 
 211546_x_at 
synuclein, alpha (non A4 component of amyloid 
precursor) SNCA 
 221772_s_at protein phosphatase 2, regulatory subunit B, delta isoform PPP2R2D 
 238886_at transmembrane emp24-like trafficking protein 10 (yeast TMED10 
 223041_at CD99 molecule-like 2 CD99L2 
 242814_at serpin peptidase inhibitor, clade B (ovalbumin), member  SERPINB9 
 227802_at RUN and FYVE domain containing 3 RUFY3 
 220646_s_at killer cell lectin-like receptor subfamily F, member 1 KLRF1 
 227259_at CD47 molecule CD47 
 225097_at homeodomain interacting protein kinase 2 HIPK2 
 203235_at thimet oligopeptidase 1 THOP1 
 204738_s_at KRIT1, ankyrin repeat containing KRIT1 
 210235_s_at 
protein tyrosine phosphatase, receptor type, f polypeptide 
(PTPRF), interacting protein (liprin), alpha 1 PPFIA1 
 223531_x_at 
G protein-coupled receptor 89A 
G protein-coupled receptor 89B 
GPR89A 
GPR89B 
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G protein-coupled receptor 89C GPR89C 
    
 Glucose/Lipid/Protein metabolism  
 234762_x_at Neurolysin (metallopeptidase) M3 family NLN 
 1558561_at histocompatibility (minor) 13 HM13 
 202323_s_at acyl-Coenzyme A binding domain containing 3 ACBD3 
 206709_x_at glutamic-pyruvate transaminase (alanine aminotransferase GPT 
 204142_at enolase superfamily member  ENOSF1 
 227960_s_at fumarylacetoacetate hydrolase domain containing 1 FAHD1 
 203676_at glucosamine (N-acetyl)-6-sulfatase GNS 
 228595_at hydroxysteroid (17-beta) dehydrogenase 1 HSD17B1 
 218533_s_at uridine-cytidine kinase 1-like 1 UCKL1 
 202735_at emopamil binding protein (sterol isomerase EBP 
 214765_s_at N-acylethanolamine acid amidase NAAA 
 202458_at protease, serine, 23 PRSS23 
    
 Others   
 217317_s_at 
hect domain and RLD 2 pseudogene 2 
hect domain and RLD 2 pseudogene 3 
hect domain and RLD 2 pseudogene 
HERC2P2 
HERC2P3 
LOC440248 
 214695_at ubiquitin associated protein 2 UBAP2L 
 232516_x_at unknown    
 231225_at Unknown  
 236191_at Unknown  
 242558_at Unknown  
 240061_at Pigeon homolog (Drosophila PION 
 222559_s_at regulation of nuclear pre-mRNA domain containing 1A RPRD1A 
 230388_s_at hypothetical protein LOC644246 LOC644246 
 233319_x_at Unknown  
 233554_at Unknown  
 229063_s_at coiled-coil domain containing 107 CCDC107 
 213367_at hypothetical LOC791120 LOC791120 
 1562849_at Unknown  
 240326_at Unknown  
 232775_at Unknown  
 214656_x_at myosin IC MYO1C 
 203940_s_at vasohibin 1 VASH1 
 205010_at guanine nucleotide binding protein-like 3 (nucleolar) like GNL3L 
 230946_at Formin 2 FMN2 
 217446_x_at Unknown  
 217891_at chromosome 16 open reading frame 58 C16orf58 
 223039_at chromosome 22 open reading frame 13 C22orf1 
 240188_at Unknown  
 215587_x_at Unknown  
 223175_s_at fem-1 homolog a (C. elegans) FEM1A 
 205495_s_at Granulysin GNLY 
 233757_x_at Unknown  
 215204_at Unknown  
 207840_at CD160 molecule CD160 
 204461_x_at RAD1 homolog (S. pombe) RAD1 
 243088_at Unknown  
 237588_at Unknown  
 222781_s_at chromosome 9 open reading frame 40 C9orf4 
 220696_at PRO0478 protein PRO0478 
 215652_at 
hypothetical LOC647081 
succinate dehydrogenase complex, subunit D, integral 
membrane protein 
LOC647081 
SDHD 
 37943_at zinc finger, FYVE domain containing 26 ZFYVE26 
 218519_at solute carrier family 35, member A5 SLC35A5 
 232253_at Hypothetical gene supported by AK128882 LOC441108 
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 244633_at Unknown  
 242077_x_at chromosome 6 open reading frame 150 C6orf15 
 221824_s_at membrane-associated ring finger (C3HC4) 8 MARCH8 
 239591_at Unknown  
 209516_at SMYD family SMYD5 
 226928_x_at Solute carrier family 25, member 37 SLC25A37 
 1557457_at Unknown  
 228788_at yippee-like 1 (Drosophila) YPEL1 
 1558525_at hypothetical protein LOC283901 LOC283901 
 228947_x_at transmembrane protein 204 TMEM204 
 241373_at Unknown  
 222692_s_at fibronectin type III domain containing 3B FNDC3B 
 229035_s_at kelch domain containing  KLHDC4 
 203919_at transcription elongation factor A (SII), 2 TCEA2 
 1553177_at SH2 domain containing 1B SH2D1B 
 1562505_at Unknown  
 216586_at Unknown  
 239137_x_at chromosome 6 open reading frame 223 C6orf223 
 221992_at similar to nuclear pore complex interacting protein LOC440348 
 1556588_at chromosome 15 open reading frame 37 C15orf37 
 236966_at armadillo repeat containing 8 ARMC8 
 231658_x_at Unkkown  
 233321_x_at hypothetical protein BC001742 LOC90834 
 
 
 
 
